Azenta earnings release, August 4, 2026

Azenta, Inc. (AZTA) · Form 8-K, Item 2.02 · Filed · SEC filing

Azenta Reports Third Quarter Results for Fiscal 2026, Ended June 30, 2026.

BURLINGTON, Mass., August 4, 2026 (PR Newswire) – Azenta, Inc. (Nasdaq: AZTA) today reported financial results for the third quarter ended June 30, 2026.

The results of B Medical Systems are reported as discontinued operations and reflected in total diluted EPS. The Company entered into a definitive agreement to sell the business during fiscal 2025, and the transaction closed on July 1, 2026, on the terms described in the Company’s Current Report on Form 8-K filed on July 8, 2026.

(1)

Reflects revisions for an immaterial classification error among cost of revenue, research and development expenses, and selling, general and administrative expenses, and other immaterial adjustments, as further described in the Annual Report on Form 10-K for the fiscal year ended September 30, 2025.

Management Comments

"Despite an uneven and challenging market backdrop, our third quarter results exceeded our expectations, with continued strength in our recurring revenue businesses, and a modest improvement in Multiomics in North America," said John Marotta, President and Chief Executive Officer. "While these results represent an encouraging step forward, our turnaround continues, and we remain focused on executing against our strategic priorities."

Third Quarter Fiscal 2026 Results - Continuing Operations

• Revenue was $161 million, up 12% year over year. Organic revenue, which excludes a 1-percentage point impact from foreign exchange and a 3-percentage point impact from the acquisition of UK Biocentre Limited, was up 9% year over year, reflecting higher revenue in Sample Management Solutions and Multiomics.

• Sample Management Solutions revenue was $88 million, up 14% year over year.¹

◦ Organic revenue, which excludes the impact from foreign exchange and the contribution from the acquisition of UK Biocentre Limited, was up 9%, mainly driven by higher revenue in Sample Repository Solutions and Consumables and Instruments, partially offset by lower revenue in Automated Stores.

• Multiomics revenue was $73 million, up 10% year over year.

◦ Organic revenue, which excludes the impact from foreign exchange, was up 8% year over year, primarily driven by higher revenue in Next Generation Sequencing and Gene Synthesis, partially offset by lower Sanger Sequencing revenue.

Summary of GAAP Earnings Results - Continuing Operations

• Operating loss was $4.2 million. Operating margin was (2.6%), down 131 basis points year over year.

◦ Gross margin was 44.9%, a decrease of 130 basis points year over year, primarily driven by unfavorable fixed-cost absorption associated with lower sales volumes in certain areas of the portfolio as well as costs related to quality remediation and rework activities in Automated Stores. These impacts were partially offset by improved operating leverage and the benefits of ongoing cost initiatives.

◦ Operating expenses in the quarter were $77 million, up 12% year over year, driven by higher research and development expenses and higher selling, general and administrative expenses, partially offset by lower restructuring and transformation charges.

• Total other income included $4 million of net interest income, versus $5 million in the prior year period.

• Diluted EPS from continuing operations was ($0.03) compared to ($0.01) in the third quarter of fiscal year 2025. Diluted EPS from discontinued operations was $0.09, compared to ($1.04) a year ago. Total diluted EPS was $0.05, compared to ($1.05) a year ago.

Summary of Non-GAAP Earnings Results - Continuing Operations

• Adjusted operating income was $4.7 million. Adjusted operating margin was 2.9%, a decrease of 180 basis points year over year.

◦ Adjusted gross margin was 46.2%, down 140 basis points compared to the third quarter of fiscal 2025, primarily driven by unfavorable fixed-cost absorption associated with lower sales volumes in certain areas of the portfolio as well as costs related to quality remediation and rework activities in Automated Stores. These impacts were partially offset by improved operating leverage and the benefits of ongoing cost initiatives.

◦ Adjusted operating expenses in the quarter were $70 million, up 13% year over year, driven by higher selling, general and administrative expenses and higher research and development expenses.

• Adjusted EBITDA was $18.5 million, and Adjusted EBITDA margin was 11.4%, a decrease of 60 basis points year over year.

• Non-GAAP Diluted EPS was $0.16, compared to $0.17 one year ago.

Cash and Liquidity as of June 30, 2026

• The Company ended the quarter with a total balance of cash, cash equivalents, restricted cash and marketable securities of $529 million.

• Operating cash flow was $1 million in the quarter. Capital expenditures were $7 million, and free cash flow (cash flow from operations less capital expenditures) was negative $5 million.

Share Repurchase Program Update

• On December 8, 2025, our Board of Directors approved a share repurchase program authorizing the repurchase of up to $250 million of our common stock through December 31, 2028, or the 2025 Repurchase Program. Repurchases under the 2025 Repurchase Program may be made in the open market or through privately negotiated transactions (including under an accelerated share repurchase agreement), or by other means, including through the use of trading plans intended to qualify under Rule 10b5-1 under the Exchange Act, subject to market and business conditions, legal requirements, and other factors. As of June 30, 2026, the Company repurchased 2.3 million shares of common stock for $50.0 million (excluding fees, commissions, and excise tax) pursuant to the 2025 Repurchase Program. All shares of common stock repurchased under the 2025 Repurchase Program have been retired.²

Fourth Quarter Fiscal 2026 Guidance - Continuing Operations

• ... (truncated)e acquisition of UK Biocentre Limited, is expected to decline approximately in the low single digits relative to the fourth quarter of fiscal 2025.

• Adjusted EBITDA is expected to range approximately between $20 million and $23 million.

Full Year Fiscal 2026 Guidance - Continuing Operations

The Company now expects total reported revenue from continuing operations to range approximately between $613 to $618 million, compared to prior guidance of $603 to $621 million for the fiscal year ending September 30, 2026.

• Total organic revenue, which excludes the impact of foreign exchange and the contribution from the acquisition of UK Biocentre Limited, is now expected to range approximately between flat to up 1%, compared to prior guidance of down 2% to up 1% relative to fiscal 2025.

◦ Organic revenue for Sample Management Solutions is expected to grow low-single-digits, consistent with prior guidance.

◦ Organic revenue for Multiomics is now expected to range approximately between down 1% to flat, compared to prior guidance of down mid-single-digits.

• Adjusted EBITDA is expected to be in the range of $59 million to $62 million, including an anticipated impact of approximately 30 basis points of margin dilution from the UK Biocentre acquisition.

• Free cash flow (cash flow from operations less capital expenditures) is expected to improve approximately 10% to 15% year-over-year, consistent with prior guidance.

Azenta does not provide forward-looking guidance on a GAAP basis for the measures on which it provides forward-looking non-GAAP guidance as the Company is unable to provide a quantitative reconciliation of forward-looking non-GAAP measures to the most directly comparable forward-looking GAAP measure, without unreasonable effort, because of the inherent difficulty in accurately forecasting the occurrence and financial impact of the various adjusting items necessary for such reconciliations that have not yet occurred, are dependent on various factors, are out of the Company's control, or cannot be reasonably predicted. Such adjustments include, but are not limited to, transformation costs, restructuring charges, costs related to acquisitions and divestitures, governance-related matters, goodwill and intangible impairments, stock-based compensation, and other gains and charges that are not representative of the normal operations of the business.

Conference Call and Webcast

Azenta management will webcast its third quarter fiscal 2026 earnings conference call on August 5, 2026 at 8:30 a.m. Eastern Time. During the call, Company management will respond to questions concerning, but not limited to, the Company's financial performance, business conditions and industry outlook. Management's responses could contain information that has not been previously disclosed.

The call will be broadcast live over the Internet and, together with presentation materials and supplemental information referenced on the call, will be hosted at the Investor Relations section of Azenta’s website at https://investors.azenta.com/events. The supplemental information is being posted at the time of this earnings release, and the presentation materials will be posted ahead of the earnings call. A replay of the webcast will be archived on the website for convenient on-demand access.

Regulation G – Use of Non-GAAP Financial Measures

This release includes non-GAAP financial measures, including organic revenue, adjusted gross profit and margin, adjusted operating income, expenses and margin, EBITDA, Adjusted EBITDA and Adjusted EBITDA margin, non-GAAP net income, non-GAAP diluted EPS and free cash flow. Management believes these measures give investors additional insight into the results of business operations, improve period-to-period comparability and facilitate comparison with peers. Management uses these measures to evaluate business performance and uses organic revenue (referred to as Core Revenue in the Company’s proxy statement), Adjusted EBITDA and free cash flow in determining compensation under the Company’s annual incentive plan. They are not presented in accordance with, and are not a substitute for, U.S. generally accepted accounting principles, or GAAP, should always be considered together with the most directly comparable GAAP measures, and may not be comparable to similarly titled measures used by other companies. These measures are presented on a continuing operations basis, except free cash flow, which is presented on a total company basis inclusive of B Medical Systems. Non-GAAP diluted EPS does not exclude stock-based compensation; the Company separately presents non-GAAP adjusted net income excluding stock-based compensation. Reconciliations to the most directly comparable GAAP measures, and descriptions of the adjustments, are included at the end of this release under “Notes on Non-GAAP Financial Measures.” Certain amounts may not sum due to rounding, and all percentages are calculated using unrounded amounts.³

“Safe Harbor Statement” under Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended

S... (truncated)nal, commercial and organizational transformation initiatives; anticipated productivity improvements and cost actions; expectations regarding demand trends and end market conditions; statements regarding the Company’s long range plan and multi-year financial targets, including the extension of the long range plan timeline to 2029.

Factors that could cause actual results to differ materially from those expressed or implied by forward looking statements include, but are not limited to: the Company’s ability to execute on and realize the expected benefits from its transformation and operational improvement initiatives; changes in customer demand, purchasing behavior or funding conditions in the markets the Company serves; macroeconomic, geopolitical or regulatory developments; the impact of foreign currency fluctuations; the Company’s ability to effectively manage costs, improve productivity and achieve anticipated margin improvements; supply chain disruptions; competitive dynamics; the ability of customers to meet payment obligations; risks relating to the collectability and timely repayment of the $35 million secured vendor loan extended to the buyer in connection with the B Medical Systems divestiture, including the buyer's ability to obtain permanent financing, the sufficiency of the collateral securing the loan, and the potential for an associated charge or impairment; and other risks and uncertainties described in the Company’s filings with the Securities and Exchange Commission, including but not limited to its Annual Report on Form 10 K, Quarterly Reports on Form 10 Q and Current Reports on Form 8 K. Because forward looking statements relate to future events and are based on current expectations, they are inherently subject to significant uncertainties, particularly with respect to projections and assumptions extending over multiple years. As a result, actual outcomes may differ materially from those projected.

Financial statements

Income Statement

Quarter Ended (in millions)

Quarter Ended – June 30, – 2026Quarter Ended – March 31, – 2026Quarter Ended – June 30, – 2025(1)Quarter Ended – Change – Prior QtrQuarter Ended – Change – Prior Yr.
Revenue from Continuing Operations1611451441112
Organic growth9
Sample Management Solutions888178914
Multiomics7364661410
Diluted EPS Continuing Operations-0.03-3.41-0.0199NM
Diluted EPS Total0.05-3.49-1.05NMNM
Non-GAAP Diluted EPS Continuing Operations0.16-0.040.17NM-6
Adjusted EBITDA - Continuing Operations18817NM6
Adjusted EBITDA Margin - Continuing Operations11.4%5.4%12.1%

Income Statement

Three Months Ended June 30, — (In thousands, except per share data)

Three Months Ended June 30, – 2026Three Months Ended June 30, – 2025Nine Months Ended June 30, – 2026Nine Months Ended June 30, – 2025
RevenueProducts41,25939,387119,985125,169
RevenueServices119,919104,468334,630309,460
RevenueTotal revenue161,178143,855454,615434,629
Cost of revenueProducts25,01819,57271,88968,607
Cost of revenueServices63,80457,879184,629168,016
Cost of revenueTotal cost of revenue88,82277,451256,518236,623
Cost of revenueGross profit72,35666,404198,097198,006
Operating expensesResearch and development8,8537,41727,47522,132
Operating expensesSelling, general and administrative67,16860,083195,666199,854
Operating expensesImpairment of goodwill and intangible assets149,083
Operating expensesRestructuring charges5137543,0784,765
Operating expensesTotal operating expenses76,53468,254375,302226,751
Operating expensesOperating loss-4,178-1,850-177,205-28,745
Other income (expense)Interest income, net3,8254,97313,31013,760
Other income (expense)Other income (expense), net1,199-8205,3371,542
Other income (expense)Income (loss) from continuing operations before income taxes8462,303-158,558-13,443
Other income (expense)Income tax expense2,3752,6355,18213,752
Other income (expense)Loss from continuing operations-1,529-332-163,740-27,195
Other income (expense)Income (loss) from discontinued operations, net of tax3,985-47,655-10,034-79,445
Other income (expense)Net income (loss)2,456-47,987-173,774-106,640
Basic net income (loss) per share:Loss from continuing operations-0.03-0.01-3.58-0.59
Basic net income (loss) per share:Income (loss) from discontinued operations, net of tax0.09-1.04-0.22-1.74
Basic net income (loss) per share:Basic net income (loss) per share0.05-1.05-3.8-2.33
Diluted net income (loss) per share:Loss from continuing operations-0.03-0.01-3.58-0.59
Diluted net income (loss) per share:Income (loss) from discontinued operations, net of tax0.09-1.04-0.22-1.74
Diluted net income (loss) per share:Diluted net income (loss) per share0.05-1.05-3.8-2.33
Weighted average shares used in computing net income (loss) per share:Basic45,28645,78045,75945,712
Weighted average shares used in computing net income (loss) per share:Diluted45,28645,78045,75945,712

Income Statement

Quarter Ended (in thousands)

Quarter Ended – June 30, 2026 – $Quarter Ended – June 30, 2026 – per diluted shareQuarter Ended – March 31, 2026 – $Quarter Ended – March 31, 2026 – per diluted shareQuarter Ended – June 30, 2025(*) – $Quarter Ended – June 30, 2025(*) – per diluted share
Net loss from continuing operations-1,529-0.03-157,021-3.41-332-0.01
Adjustments:Amortization of completed technology2,0820.052,0760.052,0680.05
Adjustments:Amortization of other intangible assets3,6160.083,5630.084,1230.09
Adjustments:Transformation costs(1)2720.014400.011,5420.03
Adjustments:Restructuring charges5130.011,4220.037540.02
Adjustments:Impairment of goodwill and intangible assets(2)149,0833.24
Adjustments:Merger and acquisition costs(3)2,2480.052,1750.05580
Adjustments:Non-recurring other adjustments(4)0-3,858-0.08380
Adjustments:Purchase accounting adjustments1540
Adjustments:Tax effect of adjustments-19803310.01-534-0.01
Adjustments:Other adjustments130
Adjustments:Non-GAAP adjusted net income (loss) from continuing operations7,1580.16-1,776-0.047,7170.17
Adjustments:Stock-based compensation, pre-tax4,6920.16,2680.143,0450.07
Adjustments:Tax rate131317
Adjustments:Stock-based compensation, net of tax4,0820.095,4530.122,5360.06
Adjustments:Non-GAAP adjusted net income excluding stock-based compensation - continuing operations11,2400.253,6770.0810,2530.22
Adjustments:Shares used in computing non-GAAP diluted net income per share45,28646,06345,780

Income Statement

Nine Months Ended (in thousands)

Nine Months Ended – June 30, 2026 – $Nine Months Ended – June 30, 2026 – per diluted shareNine Months Ended – June 30, 2025(*) – $Nine Months Ended – June 30, 2025(*) – per diluted share
Net loss from continuing operations-163,740-3.58-27,195-0.59
Adjustments:Amortization of completed technology6,0170.135,8760.13
Adjustments:Amortization of other intangible assets10,7300.2312,4990.27
Adjustments:Transformation costs(1)1,9130.049,7710.21
Adjustments:Restructuring charges3,0780.074,7650.1

Income Statement

Quarter Ended (in thousands)

Quarter Ended – June 30, 2026Quarter Ended – March 31, 2026Quarter Ended – June 30, 2025(*)Nine Months Ended – June 30, 2026Nine Months Ended – June 30, 2025(*)
GAAP net loss2,456-160,798-47,987-173,774-106,640
Less: Loss from discontinued operations3,985-3,777-47,655-10,034-79,445
GAAP net loss from continuing operations-1,529-157,021-332-163,740-27,195
Adjustments:Interest income, net-3,825-4,387-4,973-13,310-13,760
Adjustments:Income tax expense2,375-3232,6355,18213,752
Adjustments:Depreciation7,8618,3388,39924,40623,695
Adjustments:Amortization of completed technology2,0822,0762,0686,0175,876
Adjustments:Amortization of other intangible assets3,6163,5634,12310,73012,499
Adjustments:Earnings before interest, taxes, depreciation and amortization - Continuing operations10,580-147,75411,920-130,71514,867

Income Statement

Quarter Ended (in thousands)

Quarter Ended – June 30, 2026Quarter Ended – June 30, 2026Quarter Ended – March 31, 2026Quarter Ended – March 31, 2026Quarter Ended – June 30, 2025(*)Quarter Ended – June 30, 2025(*)
GAAP gross profit72,35644.962,03542.866,40446.2
Adjustments:Amortization of completed technology2,0821.32,0761.42,0681.4
Adjustments:Other Adjustments250
Adjustments:Non-GAAP adjusted gross profit74,43846.264,11144.368,49747.6

Income Statement

Nine Months Ended (in thousands)

Nine Months Ended – June 30, 2026Nine Months Ended – June 30, 2026Nine Months Ended – June 30, 2025(*)Nine Months Ended – June 30, 2025(*)
GAAP gross profit198,09743.6198,00645.6
Adjustments:Amortization of completed technology6,0171.35,8761.4
Adjustments:Transformation costs(1)510
Adjustments:Other Adjustments250
Adjustments:Non-GAAP adjusted gross profit204,11444.9203,95846.9

Income Statement

Sample Management Solutions – Quarter Ended – June 30, 2026Sample Management Solutions – Quarter Ended – June 30, 2026Sample Management Solutions – Quarter Ended – March 31, 2026Sample Management Solutions – Quarter Ended – March 31, 2026Sample Management Solutions – Quarter Ended – June 30, 2025(*)Sample Management Solutions – Quarter Ended – June 30, 2025(*)Multiomics – Quarter Ended – June 30, 2026Multiomics – Quarter Ended – June 30, 2026Multiomics – Quarter Ended – March 31, 2026Multiomics – Quarter Ended – March 31, 2026Multiomics – Quarter Ended – June 30, 2025(*)Multiomics – Quarter Ended – June 30, 2025(*)
GAAP gross profit39,12644.337,08445.740,18051.833,23045.624,95139.226,22439.6
Adjustments:Amortization of completed technology1,3931.61,3891.71,2081.66890.96871.18601.3
Adjustments:Other Adjustments250
Adjustments:Non-GAAP adjusted gross profit40,51945.938,47347.441,41353.433,91946.525,63840.227,08440.9

Income Statement

Sample Management Solutions – Nine Months Ended – June 30, 2026Sample Management Solutions – Nine Months Ended – June 30, 2026Sample Management Solutions – Nine Months Ended – June 30, 2025(*)Sample Management Solutions – Nine Months Ended – June 30, 2025(*)Multiomics – Nine Months Ended – June 30, 2026Multiomics – Nine Months Ended – June 30, 2026Multiomics – Nine Months Ended – June 30, 2025(*)Multiomics – Nine Months Ended – June 30, 2025(*)
GAAP gross profit111,99344.7115,47148.486,10442.282,53542.1
Adjustments:Amortization of completed technology3,9581.63,2961.42,05912,5801.3
Adjustments:Transformation costs(1)510
Adjustments:Other Adjustments250$—$—
Adjustments:Non-GAAP adjusted gross profit115,95146.2118,84349.888,16343.385,11543.4

Income Statement

Total Segments – Quarter Ended – June 30, 2026Total Segments – Quarter Ended – March 31, 2026Total Segments – Quarter Ended – June 30, 2025(*)Corporate – Quarter Ended – June 30, 2026Corporate – Quarter Ended – March 31, 2026Corporate – Quarter Ended – June 30, 2025(*)Total – Quarter Ended – June 30, 2026Total – Quarter Ended – March 31, 2026Total – Quarter Ended – June 30, 2025(*)
GAAP operating loss2,0514,505-6,229-156,699-6,355-4,178-165,790-1,850
Adjustments:Amortization of completed technology2,0822,0682,0822,0762,068
Adjustments:Amortization of other intangible assets493,5673,5634,1233,6163,5634,123

Income Statement

Total Segments – Nine Months Ended – June 30, 2026Total Segments – Nine Months Ended – June 30, 2025(*)Corporate – Nine Months Ended – June 30, 2026Corporate – Nine Months Ended – June 30, 2025(*)Total – Nine Months Ended – June 30, 2026Total – Nine Months Ended – June 30, 2025(*)
GAAP operating loss-8,355-2,276-168,850-26,469-177,205-28,745
Adjustments:Amortization of completed technology6,0175,8766,0175,876
Adjustments:Amortization of other intangible assets4910,68112,49910,73012,499
Adjustments:Transformation costs(1)1682,8771,7456,8941,9139,771
Adjustments:Restructuring charges3,0784,7653,0784,765
Adjustments:Impairment of goodwill and intangible assets(2)149,083149,083
Adjustments:Merger and acquisition costs(3)2044,2322,3164,4362,316
Adjustments:Purchase accounting and other adjustments17540-517535
Adjustments:Non-GAAP adjusted operating income (loss)-1,7426,517-31-1,7736,517

Balance Sheet

(In thousands, except share and per share data)

June 30, 2026September 30, 2025
Current assetsCash and cash equivalents189,654279,783
Current assetsShort-term marketable securities136,14361,137
Current assetsAccounts receivable, net of allowance for expected credit losses ($3,953 and $4,649, respectively)143,675142,181
Current assetsInventories79,08274,956
Current assetsShort-term restricted cash2,4142,359
Current assetsRefundable income taxes5,8469,728
Current assetsPrepaid expenses and other current assets53,15064,660
Current assetsCurrent assets held for sale71,38773,535
Current assetsTotal current assets681,351708,339
Current assetsProperty, plant and equipment, net172,427153,954
Current assetsLong-term marketable securities196,087201,585
Current assetsLong-term deferred tax assets494726
Current assetsOperating lease right-of-use assets61,42154,048
Current assetsGoodwill547,457702,395
Current assetsIntangible assets, net85,688101,814
Current assetsLong-term income taxes receivable45,60045,600
Current assetsOther assets8,9976,115
Current assetsNoncurrent assets held for sale76,68985,006
Current assetsTotal assets1,876,2112,059,582
Current liabilitiesAccounts payable39,38137,722
Current liabilitiesDeferred revenue36,04131,569
Current liabilitiesDerivative liability28,43533,420
Current liabilitiesAccrued warranty and retrofit costs4,0474,713
Current liabilitiesAccrued compensation and benefits30,96535,799
Current liabilitiesCustomer deposits35,35526,499
Current liabilitiesAccrued income taxes payable6,7759,416
Current liabilitiesDeposit received for the sale of B Medical Systems business28,000
Current liabilitiesAccrued expenses and other current liabilities34,24930,268
Current liabilitiesCurrent liabilities held for sale29,32628,268
Current liabilitiesTotal current liabilities272,574237,674
Current liabilitiesLong-term deferred tax liabilities15,83618,245
Current liabilitiesLong-term operating lease liabilities53,96751,244
Current liabilitiesOther long-term liabilities10,72511,142
Current liabilitiesNoncurrent liabilities held for sale12,98014,291
Current liabilitiesTotal liabilities366,082332,596
Stockholders' equityCommon stock, $0.01 par value - 125,000,000 shares authorized, 57,226,616 shares issued and 43,764,747 shares outstanding at June 30, 2026; 59,320,848 shares issued and 45,858,979 shares outstanding at September 30, 2025572594
Stockholders' equityAdditional paid-in capital493,071529,605
Stockholders' equityAccumulated other comprehensive loss-28,740-22,213
Stockholders' equityTreasury stock, at cost - 13,461,869 shares at June 30, 2026 and September 30, 2025-200,956-200,956
Stockholders' equityRetained earnings1,246,1821,419,956
Stockholders' equityTotal stockholders' equity1,510,1291,726,986
Stockholders' equityTotal liabilities and stockholders' equity1,876,2112,059,582

Cash Flow

Nine Months Ended June 30, — (In thousands) (in thousands)

Nine Months Ended June 30, – 2026Nine Months Ended June 30, – 2025
Cash flows from operating activitiesNet loss-173,774-106,640
Adjustments to reconcile net loss to net cash provided by operating activities:Depreciation and amortization41,23046,775
Adjustments to reconcile net loss to net cash provided by operating activities:Impairment of goodwill and intangible assets149,083
Adjustments to reconcile net loss to net cash provided by operating activities:Non-cash gain from settlement of preexisting contractual relationship-3,858
Adjustments to reconcile net loss to net cash provided by operating activities:Loss on assets held for sale9,49192,706
Adjustments to reconcile net loss to net cash provided by operating activities:Inventory write-downs and other non-cash items1,3013,866
Full release

Azenta expressly disclaims any obligation or undertaking to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

About Azenta Life Sciences

Azenta, Inc. (Nasdaq: AZTA) is a leading provider of life sciences solutions worldwide, enabling life science organizations around the world to bring impactful breakthroughs and therapies to market faster. Azenta provides a full suite of reliable cold-chain sample management solutions and multiomics services across areas such as drug development, clinical research and advanced cell therapies for the industry's top pharmaceutical, biotech, academic and healthcare institutions globally. Our global team delivers and supports these products and services through our industry-leading brands, including GENEWIZ, FluidX, Ziath, 4titude, Limfinity, Freezer Pro, and Barkey.

Azenta is headquartered in Burlington, Massachusetts, with operations in North America, Europe, and Asia. For more information, please visit www.azenta.com.

AZENTA INVESTOR CONTACTS:

Yvonne Perron

Vice President, Financial Planning & Analysis and Investor Relations ir@azenta.com

Maria Isabel Cuartas

Manager Investor Relations ir@azenta.com⁴

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Azenta earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.